According to Reuters, Global Blood Therapeutics (GBT) approached by Novo Nordisk (NVO)

  • March 9, 2017

Danish drugmaker Novo Nordisk (NVO) has approached Global Blood Therapeutics (GBT), a U.S. biotechnology company focused on serious blood disorders, to discuss a potential acquisition, people familiar with the matter said.

Update(s):

March 9, 2017: Novo Nordisk’s (NVO) new chief executive is looking at making acquisitions to broaden the Danish drugmaker’s product line-up, in a change of tack that reflects a need for fresh sources of growth at the world’s biggest diabetes company.

May 12, 2017: Novo Nordisk’s (NVO) new chief executive is looking at making acquisitions to broaden the Danish drugmaker’s product line-up, in a change of tack that reflects a need for fresh sources of growth at the world’s biggest diabetes company.